Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 77-84 , March 2007

The role of autologous transplantation for acute myeloid leukemia in first and second remission

  • Charles Linker, MD (Professor of Medicine and Director, Hematologic Malignancies and Bone Marrow Transplant Program, University of California San Francisco)

      Affiliations

    • Corresponding Author InformationTel.: +1 415 353 2737; Fax: +1 415 353 2545.

References 

  1. Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. The New England Journal of Medicine. 1986;315:141–147
  2. Blume KG, Forman SJ. High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies. Blut. 1987;55:49–53
  3. Linker CA, Damon LE, Ries CA, et al. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Seminars in Oncology. 1993;20:40–48
  4. Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993;81:311–318
  5. Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplantation. 1998;22:865–872
  6. Estey E, Thall PF, Pierce S, et al. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. Journal of Clinical Oncology. 1997;15:483–490
  7. Mandelli F. New strategies for the treatment of acute promyelocytic leukaemia. Journal of Internal Medicine Supplement. 1997;740:23–27
  8. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation. 2003;31:731–738
  9. Gorin NC, Labopin M, Fouillard L, et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation. 1996;18:111–117
  10. Stein AS, O'donnell MR, Chai A, et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. Journal of Clinical Oncology. 1996;14:2206–2216
  11. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. The New England Journal of Medicine. 1995;332:217–223
  12. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. The New England Journal of Medicine. 1998;339:1649–1656
  13. Gorin NC, Labopin M. Treatment of acute myeloid leukemia. The New England Journal of Medicine. 1999;340:1437
  14. Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Journal of Clinical Oncology. 1997;15:833–839
  15. Damon LE, Mass R, Linker CA. The association between high-dose cytarabine neurotoxicity and renal insufficiency. Journal of Clinical Oncology. 1989;7:1563–1568
  16. Tam JY, Blume KG, Prober CG. Prophylactic fluconazole and Candida krusei infections. The New England Journal of Medicine. 1992;326:891–893
  17. Denning DW, Stepan DE, Blume KG, Stevens DA. Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. The Journal of Infection. 1992;24:73–79
  18. Linker CA, Ries CA, Damon LE, et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biology of Blood and Marrow Transplantation. 2000;6:50–57
  19. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998;351:700–708
  20. Olivieri A, Offidani M, Montanari M, et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica. 1998;83:329–337
  21. Hermouet S, Niaussat AE, Briec A, et al. Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products. Hematology and Cell Therapy. 1997;39:317–325
  22. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–3969
  23. Gunn N, Damon L, Varosy P, et al. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biology of Blood and Marrow Transplantation. 2003;9:643–648
  24. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. The New England Journal of Medicine. 2005;353:2433–2441
  25. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. The New England Journal of Medicine. 2005;353:2442–2449
  26. Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Current Opinion in Immunology. 2006;18:599–604
  27. Linker CA, Damon LE, Ries CA, et al. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplantation. 2002;29:297–301
  28. Linker C, George S, Hurd DD, Larson RA. Autologous stem cell transplantation for acute myeloid leukemia in second remission. Blood. 2001;98:689a
  29. Kolitz JE, George SL, Dodge RK, et al. Consolidation therapy by cytogenetic risk in adults with AML < 60 years in first complete remission. Blood. 2001;98:688a
  30. Tallman MS, Perez W, Keating A, et al. Pretransplant consolidation chemotherapy decreases leukemia relapse after autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML) in first remission (CR). Blood. 2001;98:859a;(abstract)

PII: S1521-6926(06)00087-9

doi: 10.1016/j.beha.2006.11.007

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 77-84 , March 2007

Article Tools